TScan Therapeutics

Cell Therapy Biotechnology Global workforce; Waltham, Massachusetts headquarters
Report

Date announced

Supporting source

U.S. Securities and Exchange Commission Official filing

Layoff Summary

TScan Therapeutics is cutting about 75% of its workforce as it narrows its research to in-vivo cell therapies for solid tumors.

The company paused its Phase 3 ALLOHA-2 program, ended internal manufacturing and expects the reorganization to be substantially complete in the fourth quarter of 2026.

Record checked
View Database
Showing 3 announcements